Brevetoxin B

Brevetoxin B

SCHEMBL869360

C=C(C=O)C[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]3C[C@@H]4O[C@@H]5C[C@]6(C)O[C@]7(C)CC[C@@H]8O[C@@H]9C[C@]%10(C)O[C@@H]%11C(C)=CC(=O)O[C@H]%11C[C@H]%10O[C@H]9C[C@@H](C)[C@H]8O[C@H]7C[C@H]6O[C@@]5(C)C/C=C\[C@H]4O[C@H]3C[C@H]2O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 1/20 1.00
SCN2A Q99250 1/20 1.00
SCN3A Q9NY46 1/20 1.00
ALDH1A1 P00352 4/20 0.87
NPSR1 Q6W5P4 3/20 0.87
MEN1 O00255 1/20 0.87
KMT2A Q03164 1/20 0.87
PDE4D Q08499 3/20 0.87
NPC1 O15118 2/20 0.86
MAPT P10636 2/20 0.86
MAPK1 P28482 2/20 0.86
RAB9A P51151 2/20 0.86
XBP1 P17861 1/20 0.86
POLB P06746 1/20 0.82
CRHBP P24387 1/20 0.78
CRHR2 Q13324 1/20 0.78
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43
RAP1A P62834 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alpha-Bungarotoxin SCHEMBL14043478 1.00 SCN1A (1.00) SCN1ASCN2ASCN3AALDH1A1NPSR1
Alpha-Bungarotoxin SCHEMBL29366348 1.00 SCN1A (1.00) SCN1ASCN2ASCN3AALDH1A1NPSR1
Alpha-Bungarotoxin SCHEMBL29386702 1.00 SCN1A (1.00) SCN1ASCN2ASCN3AALDH1A1NPSR1
Alpha-Bungarotoxin SCHEMBL29374938 1.00 SCN1A (1.00) SCN1ASCN2ASCN3AALDH1A1NPSR1
Alpha-Bungarotoxin SCHEMBL14106557 1.00 SCN1A (1.00) SCN1ASCN2ASCN3AALDH1A1NPSR1
Alpha-Bungarotoxin SCHEMBL29381923 1.00 SCN1A (1.00) SCN1ASCN2ASCN3AALDH1A1NPSR1
SCHEMBL15502881 0.94 ALDH1A1 (0.89) SCN1ASCN2ASCN3AALDH1A1NPSR1
SCHEMBL12908959 0.93 ALDH1A1 (0.91) SCN1ASCN2ASCN3AALDH1A1NPSR1
SCHEMBL10159481 0.93 ALDH1A1 (0.91) SCN1ASCN2ASCN3AALDH1A1NPSR1
SCHEMBL10130542 0.93 ALDH1A1 (0.87) SCN1ASCN2ASCN3AALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779551-B1 Antitoxins to brevetoxin THE FLORIDA INTERNATIONAL UNIVERISTY BOARD OF TRUSTEES (US) 2023-10-10 US claimed
CN-113332967-B Trapezoidal polyether modified and cysteine terminated chromatographic stationary phase, preparation method and application 常州工程职业技术学院 2023-04-07 CN claimed
CN-113332967-A Trapezoidal polyether modified and cysteine terminated chromatographic stationary phase, preparation method and application 常州工程职业技术学院 2021-09-03 CN claimed
US-12350260-B2 Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) 2025-07-08 US disclosed
US-12351494-B1 Harmful algae bloom mitigation system FLORIDA GULF COAST UNIVERSITY BOARD OF TRUSTEES (US) 2025-07-08 US disclosed
US-20250085274-A1 BREVETOXIN DETECTION DEVICE, SYSTEM, AND METHOD MOTE MARINE LABORATORY INC (US) 2025-03-13 US disclosed
US-11779551-B1 Antitoxins to brevetoxin THE FLORIDA INTERNATIONAL UNIVERISTY BOARD OF TRUSTEES (US) 2023-10-10 US disclosed
US-11760758-B2 Mitragynine analogs for the treatment of pain, mood disorders and substance use disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-09-19 US disclosed
CN-113332967-B Trapezoidal polyether modified and cysteine terminated chromatographic stationary phase, preparation method and application 常州工程职业技术学院 2023-04-07 CN disclosed
CN-111138447-B B-group hapten, artificial antigen and monoclonal antibody of Gymnodinium breve toxin, and preparation method and application thereof 国家海洋环境监测中心 2022-09-06 CN disclosed
US-20220193048-A1 PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) 2022-06-23 US disclosed
WO-2006003456-A2 GLYCOSYLATION OF ANTIBIOTICS ISIS INNOVATION LIMITED (GB) 2006-01-12 WO disclosed
US-20050148041-A1 Sandwich assay kits for detecting shigatoxin ctx3c JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2005-07-07 US disclosed
US-20050124686-A1 Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases UNIVERSITY OF NORTH CAROLINA (US) 2005-06-09 US disclosed
US-20050124685-A1 Polyether brevetoxin derivatives as a treatment for neurotoxic shellfish poisoning and ciguatera fish poisoning UNIVERSITY OF NORTH CAROLINA AT WILMINGTON 2005-06-09 US disclosed
WO-2005027903-A1 POLYETHER BREVETOXIN DERIVATIVES AS A TREATMENT FOR NEUROTOXIC SHELLFISH POISONING AND CIGUATERA FISH POISONING UNIVESITY OF NORTH CAROLINA AT (US) 2005-03-31 WO disclosed
WO-2005028482-A1 POLYETHER BREVETOXIN DERIVATIVES AS A TREATMENT FOR CYSTIC FIBROSIS, MUCOCILIARY DYSFUNCTION, AND PULMONARY DISEASES UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) 2005-03-31 WO disclosed
US-20040077879-A1 Bis (amino acid) molecular scaffolds UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2004-04-22 US disclosed
US-20040059096-A1 Anti-ciguatoxin monoclonal antibody JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2004-03-25 US disclosed
WO-2004013282-A2 BIS (AMINO ACID) MOLECULAR SCAFFOLDS UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059096-A1 Anti-ciguatoxin monoclonal antibody PBK, IK, KLRK1 SCN1A 3060/4885SCN2A 3327/4885SCN3A 3200/4885
US-20040077879-A1 Bis (amino acid) molecular scaffolds DNPEP, BCAT1, BCAT2 SCN1A 4111/4885SCN2A 2648/4885SCN3A 2740/4885
US-20220193048-A1 PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING PRSS12, TPSB2, F2RL1 SCN1A 759/4885SCN2A 246/4885SCN3A 651/4885
US-12350260-B2 Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning PRSS12, TPSB2, F2RL1 SCN1A 759/4885SCN2A 246/4885SCN3A 651/4885
US-11760758-B2 Mitragynine analogs for the treatment of pain, mood disorders and substance use disorders DRD2, OPRK1, OPRD1 SCN1A 997/4885SCN2A 978/4885SCN3A 992/4885
US-20050148041-A1 Sandwich assay kits for detecting shigatoxin ctx3c F13A1, HTR3D, INHA SCN1A 2619/4885SCN2A 2164/4885SCN3A 235/4885
US-20050124685-A1 Polyether brevetoxin derivatives as a treatment for neurotoxic shellfish poisoning and ciguatera fish poisoning ANTXR2, QRFPR, NPY2R SCN1A 1011/4885SCN2A 886/4885SCN3A 375/4885
US-11779551-B1 Antitoxins to brevetoxin ANTXR2, MTX1, TXN SCN1A 3036/4885SCN2A 2703/4885SCN3A 1771/4885
US-20050124686-A1 Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases CFTR, MUC1, SLC47A1 SCN1A 1103/4885SCN2A 1760/4885SCN3A 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.